Patients with ‘highest clinical need’ to be offered tirzepatide first – NICE

Library image. Credit: Getty/choi dongsu

By Sarah Lowden

Only around 7% of eligible patients will be offered the weight loss drug tirzepatide in the first 3 years of its use on the NHS in England.

The National Institute for Health and Care Excellence said in its final draft guidance that the roll out “has to be carefully managed to ensure healthcare professionals can continue to meet the full range of health needs of all their patients”.